The hallmarks of cancer are a set of biological capabilities that normal cells acquire on their path to becoming malignant. First proposed by Douglas Hanahan and Robert Weinberg in a landmark 2000 paper, the framework started with six core traits and has since expanded to fourteen, giving researchers and clinicians a shared vocabulary for understanding an enormously complicated disease. Rather than cataloguing hundreds of molecular quirks in isolation, the hallmarks organize cancer’s complexity into a manageable set of functional principles, each of which represents a different way a tumor subverts the body’s normal controls.
Self-Sustaining Growth Signals
Healthy cells wait for external signals before they divide. Growth factors bind to receptors on the cell surface and trigger a cascade of internal messages that ultimately push the cell through its replication cycle. Cancer cells short-circuit this system. They can produce their own growth factors, overload their surfaces with extra receptors so that even faint signals cause a response, or carry mutations in the internal relay chain that keep the “go” signal permanently switched on. Oncogenes like ras and src work this way: they activate the signaling pathway that drives proliferation and keep it running regardless of whether an outside signal arrived.1Oncogene. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis The normal machinery for translating a growth-factor signal into cell division is essentially hijacked, so what were once tightly regulated signaling steps become engines for uncontrolled growth.2PubMed. Growth factors and cancer
Evading the Brakes on Growth
Generating your own “go” signals is only half the equation. The body also has powerful “stop” signals, tumor suppressor genes whose job is to halt division when something looks wrong. The two most prominent are the retinoblastoma protein (RB) and the p53 transcription factor; together, they act as gatekeepers for the cell cycle.3PubMed. The RB and p53 pathways in cancer When these genes are mutated or silenced, cells lose the ability to slam the brakes on division. A review of the anti-growth signaling landscape catalogues an even wider set of pathways cancer cells must overcome, including PTEN, the Hippo pathway, and several others, each representing a different cellular checkpoint that can be disabled by mutation.4PubMed Central. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds
Losing tumor suppressor function does more than just remove a speed limit. In prostate cancer, for example, simultaneous loss of p53 and RB function increases the cell’s “plasticity,” letting it change its identity and dodge treatments that depend on the cell staying a recognizable type. When researchers restored p53 and RB function in those cells, the resistance reversed.5PubMed Central. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer The takeaway is that tumor suppressors are not just about slowing growth; they also keep a cell committed to its normal identity, and losing them opens the door to far more than unchecked division.
Resisting Cell Death
When a cell’s DNA is severely damaged or its growth signals go haywire, a built-in self-destruct program called apoptosis normally kicks in. It is the body’s last-resort quality check. Cancer cells find ways around it. The BCL-2 family of proteins is central here: some members promote apoptosis and others block it. In many cancers, the anti-apoptotic members are overproduced, tipping the balance so the cell survives when it should die.6PubMed Central. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy This is not just a theoretical concern for researchers: overexpression of anti-apoptotic BCL-2 proteins is a widespread mechanism by which cancer cells resist chemotherapy, since many conventional drugs work precisely by triggering apoptosis.7PubMed. Dual-targeting Bcl-2-mediated apoptosis and synergistic pathways: Combinatorial strategies to overcome therapeutic resistance in cancer
Unlimited Replication
Even if a cell manages to keep dividing, it normally hits a wall. Every time a cell copies its DNA, the protective caps on the ends of chromosomes, called telomeres, get a little shorter. Eventually they are too short to protect the chromosome, and the cell stops dividing or dies. Cancer cells solve this problem by switching on a telomere-maintenance mechanism. Most activate telomerase, an enzyme that rebuilds those caps. A smaller fraction use an alternative approach called ALT (Alternative Lengthening of Telomeres) that achieves the same result through a different molecular route.8PubMed. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof Either way, the cell gains the ability to replicate indefinitely, which is why cancer cells in a lab dish can keep growing long after normal cells would have stopped.
Growing a Blood Supply
A tumor cannot grow beyond a tiny cluster without its own blood supply. Oxygen and nutrients only diffuse a fraction of a millimeter through tissue, so any solid tumor that wants to keep expanding needs to recruit new blood vessels, a process called angiogenesis. The key trigger is hypoxia: as cells in the interior of a growing mass run low on oxygen, they stabilize a protein called HIF-1, which switches on genes that coax nearby blood vessels to sprout branches toward the tumor.9PubMed. Regulation of redox signaling in HIF-1-dependent tumor angiogenesis HIF-1 also responds to growth factor signaling and oncogene activation, meaning it can be switched on even outside of low-oxygen conditions.10PubMed Central. Hypoxia-inducible factor-1 in tumour angiogenesis The blood vessels that tumors grow tend to be leaky and disorganized compared to normal vasculature, which paradoxically can make drug delivery to the tumor’s core more difficult.
Invasion and Metastasis
The most dangerous thing a cancer can do is spread to distant organs. For that, cells need to detach from their neighbors, invade surrounding tissue, enter the bloodstream, survive the journey, and colonize a new site. A developmental program called the epithelial-mesenchymal transition (EMT) plays a central role: it causes tightly packed epithelial cells to loosen their connections, gain mobility, and become more resistant to apoptosis.11PubMed. Epithelial Mesenchymal Transition in Tumor Metastasis EMT is a normal part of embryonic development and wound healing, but cancer co-opts it. Not every cell in a tumor undergoes EMT, and not every cell that enters the blood succeeds in colonizing a distant organ. The process is remarkably inefficient, yet even a tiny success rate, given the millions of circulating tumor cells a large tumor can shed, is enough to seed lethal metastases.
Rewiring Metabolism
Cancer cells have an unusual metabolic preference. Even when plenty of oxygen is available, they tend to break down glucose through a rapid but less efficient pathway called aerobic glycolysis, producing lactate as a byproduct. This phenomenon is known as the Warburg effect, after the biochemist who described it nearly a century ago.12PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells? On its face, it seems wasteful: aerobic glycolysis extracts far less energy per glucose molecule than the normal oxygen-dependent route. But the tradeoff buys speed and raw materials. The rapid flux of glucose through the cell generates building blocks for new DNA, membranes, and proteins, exactly what a rapidly dividing cell needs. The lactate that accumulates also acidifies the tumor environment, which in turn can impair immune cells and promote invasion.13PubMed. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression
Hiding from the Immune System
The immune system routinely detects and destroys abnormal cells. For a tumor to grow, it needs to evade this surveillance. One of the best-understood escape routes involves the PD-1/PD-L1 checkpoint. PD-1 is a receptor on T cells that, when engaged by its partner PD-L1, tells the T cell to stand down. This interaction normally prevents autoimmune damage, but many cancers exploit it by plastering PD-L1 on their surfaces, effectively hanging a “do not attack” sign for incoming immune cells.14PubMed Central. Regulatory mechanisms of PD-1/PD-L1 in cancers The clinical success of checkpoint-inhibitor drugs, which block PD-1 or PD-L1 and re-enable the immune response, is direct evidence of how important this hallmark is.
Genomic Instability and Tumor-Promoting Inflammation
Hanahan and Weinberg distinguished the hallmark capabilities from what they called “enabling characteristics,” conditions that make it easier for cells to acquire the hallmarks in the first place. Two stand out.
Genomic instability is a feature of most cancers. Normal cells have elaborate DNA-repair systems that catch and fix errors. When those repair systems are themselves mutated, the rate of new mutations rises sharply, increasing the odds that one will hit a gene controlling growth, death, or any of the other hallmarks.15PubMed Central. DNA repair defects in cancer and therapeutic opportunities Hereditary cancers often begin this way: a person inherits a faulty DNA-repair gene, and the resulting instability accelerates the accumulation of further mutations. Crucially, this vulnerability also creates a therapeutic opening, since cancer cells with broken repair machinery are more sensitive to drugs that inflict DNA damage.
Chronic inflammation is the other major enabler. An inflamed tissue environment supplies growth factors, survival signals, and enzymes that remodel surrounding tissue, all of which can nudge pre-cancerous cells toward full malignancy. The relationship is not one-directional: tumors actively recruit inflammatory cells and shape the signaling in their neighborhood to maintain a pro-tumorigenic environment.16PubMed Central. The emerging roles of inflammasome-dependent cytokines in cancer development The classic clinical examples are well known: chronic hepatitis raising liver cancer risk, inflammatory bowel disease raising colorectal cancer risk, and so on.
Newer Additions to the Framework
The original 2000 paper listed six hallmarks. By 2011, Hanahan and Weinberg added metabolic reprogramming and immune evasion (which had already been recognized but not formally included), along with the two enabling characteristics above. In 2022, the framework expanded again to include several more dimensions. Two are especially worth understanding.
Nonmutational epigenetic reprogramming refers to changes in gene activity that do not involve alterations to the DNA sequence itself. Genes can be switched on or off by chemical modifications to DNA or to the proteins that package it, and when these modifications go awry, the result can be the activation of growth-promoting genes or the silencing of tumor suppressors, all without a single mutation.17PubMed Central. Epigenetic plasticity and the hallmarks of cancer The 2022 update also proposed that polymorphic microbiomes, the communities of bacteria and other microbes living in and on the body, function as another enabling characteristic. Certain gut bacteria, for instance, can induce a state in nearby cells that causes them to secrete growth factors, feeding tumor expansion.18PLOS Pathogens. The microbiome and the hallmarks of cancer Phenotypic plasticity and disrupted differentiation, the ability of cancer cells to shift their identity and resist lineage-specific therapies, was proposed as a discrete hallmark capability in its own right.19PubMed. Hallmarks of Cancer: New Dimensions
The Tumor Microenvironment Is Not a Bystander
A tumor is not just a ball of cancer cells. It sits within a complex neighborhood of non-malignant cells, structural scaffolding, blood vessels, and immune infiltrates collectively called the tumor microenvironment. Cancer-associated fibroblasts (CAFs) are among the most important residents: they secrete signaling molecules, remodel the physical scaffolding around the tumor, and influence how immune cells behave.20PubMed Central. Cancer-Associated Fibroblasts: Master Tumor Microenvironment Modifiers CAFs interact with immune cells by releasing cytokines and other molecules that can tip the balance toward an immunosuppressive environment, helping cancer cells avoid immune detection.21PubMed Central. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives Physical forces matter too. Research on breast cancer cells has shown that the stiffness of the surrounding matrix influences whether cells adopt stem-like properties; a specific range of mechanical pressure promoted tumor-forming potential, while forces above or below that range did not.22Signal Transduction and Targeted Therapy. Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling
From Framework to Treatment
The hallmarks’ greatest practical value is as a map for drug development. If each hallmark represents a functional requirement a tumor cannot do without, then each is a potential target. Checkpoint inhibitors target immune evasion. Anti-angiogenic drugs target blood-vessel recruitment. Drugs that restore apoptotic signaling attack the resistance-to-death hallmark. The framework helps clinicians think about which capabilities a given patient’s tumor relies on and which drug might disrupt them.
The complication is that tumors are genetically diverse, even within a single patient. Different cells in the same mass may rely on different hallmarks to different degrees, and those dependencies shift over time. This is why responses to targeted therapies are often partial and temporary: knock out one capability, and tumor evolution can find an alternative route.23PubMed Central. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities Drug resistance in cancer is fundamentally an evolutionary process. Treatment imposes a selective pressure, and any cell with a pre-existing or newly acquired mutation that bypasses the drug’s target has a survival advantage.24PubMed Central. Drug resistance in cancer: molecular evolution and compensatory proliferation Personalized medicine, in which genomic profiling of a patient’s tumor guides therapy selection, is an attempt to stay ahead of this evolutionary race.25PubMed Central. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment
Criticisms of the Framework
The hallmarks model is not without critics. One recurring objection is that it is rooted in a cell-centered view of cancer: the assumption that cancer begins when individual cells accumulate mutations in key genes. An alternative perspective, the tissue organization field theory, argues that cancer is fundamentally a tissue-level disease. Under this view, all cells naturally proliferate and move, and it is the disruption of the interactions between cells and their surrounding tissue that drives malignancy, not a sequence of mutations within any single cell.26PubMed Central. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique Others have pointed out that as the hallmark list grows with each update, it risks becoming so broad that almost any feature of tumor biology can be slotted in, weakening its organizing power.27PubMed Central. Revisiting the hallmarks of cancer Still, even critics generally acknowledge the framework’s value as a teaching and communication tool. Most oncologists use the hallmarks less as a rigid checklist and more as a conceptual scaffold, a way to keep the big picture in view while dealing with the overwhelming molecular detail of individual cases.
Pediatric Cancers Play by Different Rules
The hallmarks framework was built largely on the biology of adult cancers, which are overwhelmingly driven by accumulated mutations from decades of cell division and environmental exposure. Pediatric cancers look different at the molecular level. Whole-genome sequencing has revealed that childhood tumors carry over tenfold fewer mutations per stretch of DNA than adult tumors.28PubMed Central. Developmental origins shape the pediatric cancer genome Instead of being mutation-heavy, childhood cancers tend to be driven by variants that disrupt how genes are regulated during normal development, altering chromatin state, transcriptional programs, and non-coding regulatory regions.29PubMed Central. Developmental origins shape the paediatric cancer genome This means that some of the hallmarks, especially those that depend on an accumulation of many mutations such as genomic instability, look very different in a five-year-old than in a sixty-five-year-old. Epigenetic disruption and developmental mis-wiring take center stage in ways the original framework did not anticipate.
What Large Animals Can Teach Us About Cancer Suppression
If cancer arises when individual cells go rogue, you would expect that animals with more cells would get cancer more often. A blue whale has roughly a thousand times more cells than a human. Yet large, long-lived animals do not show correspondingly higher cancer rates. This observation, known as Peto’s paradox, suggests that evolution has equipped these species with extra cancer-suppression mechanisms.30PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention
Genomic studies across dozens of mammalian species have begun to reveal what those mechanisms look like. A comparative analysis of 60 mammalian genomes found nearly 300 strongly selected genes unique to long-lived species, many of them involved in immune response, DNA repair, and cancer suppression. In bowhead whales and naked mole rats, two species famous for their longevity and cancer resistance, researchers identified a shared mutation in the LZTS1 gene that suppressed cancer development in laboratory experiments. A mutation in the YAP1 gene, found in large cetaceans, appeared to upregulate tumor-suppression pathways.31PubMed. Natural resistance to cancers in long-lived mammals: genomic mechanisms and experimental evidence to explain Peto’s paradox Some species take a brute-force approach: the microbat, which weighs only about ten grams but can live over thirty years, carries 63 copies of the tumor-suppressor gene FBXO31, while most mammals have just one. Elephants, similarly, carry extra copies of TP53, the gene most frequently mutated in human cancers.32PubMed Central. Solutions to Peto’s paradox revealed by mathematical modelling and cross-species cancer gene analysis These findings suggest that evolution has found multiple independent ways to reinforce the very hallmark-related controls, particularly DNA repair and apoptosis, that human cancers learn to dismantle.